New Hampshire Trust Sells 86 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

New Hampshire Trust lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,949 shares of the company’s stock after selling 86 shares during the period. IDEXX Laboratories comprises approximately 0.9% of New Hampshire Trust’s investment portfolio, making the stock its 28th largest holding. New Hampshire Trust’s holdings in IDEXX Laboratories were worth $3,490,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Norway Savings Bank raised its stake in IDEXX Laboratories by 5.5% in the second quarter. Norway Savings Bank now owns 3,635 shares of the company’s stock valued at $1,826,000 after buying an additional 188 shares during the period. Capital Investment Services of America Inc. raised its stake in IDEXX Laboratories by 1.7% in the second quarter. Capital Investment Services of America Inc. now owns 41,416 shares of the company’s stock valued at $20,800,000 after buying an additional 683 shares during the period. Flagship Harbor Advisors LLC raised its stake in IDEXX Laboratories by 3.6% in the second quarter. Flagship Harbor Advisors LLC now owns 3,555 shares of the company’s stock valued at $1,785,000 after buying an additional 122 shares during the period. Czech National Bank raised its stake in IDEXX Laboratories by 0.7% in the second quarter. Czech National Bank now owns 9,826 shares of the company’s stock valued at $4,935,000 after buying an additional 70 shares during the period. Finally, B.O.S.S. Retirement Advisors LLC raised its stake in IDEXX Laboratories by 3.6% in the second quarter. B.O.S.S. Retirement Advisors LLC now owns 4,771 shares of the company’s stock valued at $2,396,000 after buying an additional 168 shares during the period. Institutional investors own 86.85% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael Lane sold 16,027 shares of the firm’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $510.00, for a total value of $8,173,770.00. Following the sale, the executive vice president now owns 4,034 shares of the company’s stock, valued at approximately $2,057,340. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other IDEXX Laboratories news, EVP Michael Lane sold 16,027 shares of the firm’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $510.00, for a total value of $8,173,770.00. Following the sale, the executive vice president now owns 4,034 shares of the company’s stock, valued at approximately $2,057,340. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP James F. Polewaczyk sold 22,909 shares of the firm’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $510.56, for a total value of $11,696,419.04. Following the completion of the sale, the executive vice president now directly owns 10,038 shares in the company, valued at approximately $5,125,001.28. The disclosure for this sale can be found here. In the last quarter, insiders have sold 52,360 shares of company stock valued at $26,743,411. 2.11% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

IDXX has been the topic of a number of recent research reports. Stifel Nicolaus lowered their target price on IDEXX Laboratories from $525.00 to $500.00 and set a “hold” rating on the stock in a research note on Friday. Morgan Stanley increased their target price on IDEXX Laboratories from $590.00 to $600.00 and gave the stock an “overweight” rating in a research note on Thursday, August 3rd. StockNews.com initiated coverage on IDEXX Laboratories in a research note on Thursday, August 17th. They set a “buy” rating on the stock. Atlantic Securities lowered IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $610.00 target price on the stock. in a research note on Wednesday, August 2nd. Finally, JPMorgan Chase & Co. increased their target price on IDEXX Laboratories from $550.00 to $600.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 2nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $571.67.

IDEXX Laboratories Price Performance

NASDAQ:IDXX traded down $11.39 during trading hours on Friday, reaching $450.69. 770,079 shares of the company were exchanged, compared to its average volume of 452,822. The company has a market capitalization of $37.41 billion, a P/E ratio of 47.84, a P/E/G ratio of 2.66 and a beta of 1.20. IDEXX Laboratories, Inc. has a 1-year low of $317.06 and a 1-year high of $564.73. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.33 and a quick ratio of 0.89. The business has a 50 day moving average of $510.75 and a 200 day moving average of $490.61.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 1st. The company reported $2.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.43 by $0.24. The business had revenue of $943.63 million for the quarter, compared to the consensus estimate of $927.84 million. IDEXX Laboratories had a return on equity of 104.84% and a net margin of 22.52%. Research analysts forecast that IDEXX Laboratories, Inc. will post 9.82 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.